✦ LIBER ✦

Abnormal B-cell function in hemophiliacs treated with cryoprecipitate and factor VIII and IX concentrates

✍ Scribed by Andrew Gorski; George F. Gjerset; Paul J. Martin; Richard B. Counts; John A. Hansen

Book ID: 118374706
Publisher: Elsevier Science
Year: 1986
Tongue: English
Weight: 579 KB
Volume: 40
Category: Article
ISSN: 1090-2341
DOI: 10.1016/0090-1229(86)90189-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Comparative efficacy of nonheated and he

Comparative efficacy of nonheated and heat-treated factor IX complex concentrate in treatment of hemophiliacs with inhibitors

✍ Richard S. Schwartz; Nadia P. Ewing; Toni J. Gorenc; Joel A. Spero 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 354 KB 👁 2 views

To determine if heat-treated factor IX complex concentrate is as effective as nonheated factor IX complex concentrate for treatment of subjects with hemophilia A and antifactor Vlll antibodies (inhibitor patients), we have retrospectively reviewed consecutive home treatment records of ten inhibitor

Decreased Helper-Suppressor Cell Ratios

Decreased Helper-Suppressor Cell Ratios Following Treatment with Blood Products: Factor VIII and IX Concentrates and Fresh Frozen Plasma

✍ Ragni, M V ;Lewis, J H ;Spero, J A ;Bontempo, F A ;Rabin, B S 📂 Article 📅 2009 🏛 Wiley (Blackwell Publishing) ⚖ 49 KB

The Stimulation of Immune Antibodies Ant

The Stimulation of Immune Antibodies Anti-A and Anti-B in Patients after Treatment with Cryoprecipitate and Factor IX Concentrate (P.P.S.B. According to Soulier)

✍ R. L. McShine; V. A. J. M. Kunst 📂 Article 📅 1970 🏛 John Wiley and Sons 🌐 English ⚖ 250 KB

Use of several second generation serolog

Use of several second generation serological assays to determine the true prevalence of hepatitis C virus infection in haemophiliacs treated with non-virus inactivated factor VIII and IX concentrates

✍ Henry G. Watson; Christopher A. Ludlam; Selma Rebus; Lin Qi Zhang; John F. Peuth 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 406 KB

Clinical efficacy, safety and pharmacoki

Clinical efficacy, safety and pharmacokinetic properties of the plasma-derived factor IX concentrate Haemonine® in previously treated patients with severe haemophilia B

✍ M. SERBAN; A. B. SKOTNICKI; M. COLOVIC; C. JINCA; A. KLUKOWSKA; P. LAGUNA; D. M. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB

DDAVP does not increase factor VIII (FVI

DDAVP does not increase factor VIII (FVIII) plasma levels in patients with severe von Willebrand Disease (vWD) treated with cryoprecipitate: A. Gringeri, M. Cattaneo, L. Simoni, B. Akkawat, M.T. Canciani, B. Bottasso, P.M. Mannucci. “A. Bianchi Bonimi” Hemophilia and Thrombosis Center. Milano

📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 86 KB